

PERSONAL INFORMATIONS



Gender Male | Birth Date

PROFESSIONAL EXPERIENCE

- November 2022 – ongoing **Medical Oncology Resident:** Fourth Year Resident at Medical Oncology School in University of Naples Federico II
- October 2018 – June 2021 **Internal Student:** University of Naples Federico II Department of Endocrinology – NET
- Project:** NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIOS IN PATIENTS WITH MEDULLARY THYROID CARCINOMA: ASSOCIATION WITH DISEASE AGGRESSIVENESS

EDUCATION AND TRAINING

- July 2021 **Qualification for Profession Practice:** Registration in the Professional Register of Doctor-Surgeons and Dentists Order of Naples (Registration Number 039166)
- November 2015 – July 2022 **Master's Degree Medicine and Surgery**
- Institution:** University of Naples Federico II
Final grade: 110/110
Subject: Endocrinology
- Experimental Thesis Title:** NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYT RATIOS IN PATIENTS WITH MEDULLARY THYROID CARCINOMA: ASSOCIATION WITH DISEASE AGGRESSIVENESS
- Supervisor:** Prof. Roberta Modica
- September 2010 – June 2015 **"Istituto Ente Religioso Suore Francescane Adoratrici S.Croce Velotti" High School Classic High School Diploma - Torre Annunziata (NA),**
- Final grade:** 100/100

PROFESSIONAL SKILLS

- **BLSD- PBLSD Performer Certificate. According to ILCOR 2020- 2025 and NRC guidelines (2023).** Provided by National Rescue Council (NRC)

LANGUAGES

Mother Tongue Italian

Other Languages - **English (level B2):** Trinity Level 2 Certificate in ESOL International (First) Grade A

PUBBLICATION LIST

- **Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis.** DOI: 10.1016/j.critrevonc.2025.105092; Critical Reviews in Oncology Hematology.
- **Case Report: TPR-ALK fusion-positive inflammatory myofibroblastic tumour treated with sequential ALK inhibitors;** Frontiers in Oncology; DOI: 10.3389/fonc.2026.1778283
- **Censoring in trials testing immunotherapy in advanced cancers: a systematic review and a meta-research study;** JNCI: Journal of the National Cancer Institute; DOI: 10.1093/jnci/djaf237
- **Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma;** Translational Oncology; DOI: 10.1016/j.tranon.2025.102452;
- **Quality of life results and survival outcomes in trials of immunotherapy in advanced cancers: A systematic review and meta-research study;** Critical Reviews in Oncology Hematology; DOI: 10.1016/j.critrevonc.2025.104952;
- **Performance of Control Arms in Trials Leading to FDA Cancer Drug Approvals;** Journal of the National Comprehensive Cancer Network; DOI: 10.6004/jnccn.2025.7093.
- **Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis;** European Journal of Cancer; DOI: 10.1016/j.ejca.2024.115077

Informatic Skills Excellent command:

- Microsoft Office
- Windows Systems
- Web Browser (Chrome, Explores, Safari)
- MacOS Systems

Patente di guida Driving License B type

Personal Statement I hereby authorize the treatment of my personal data pursuant to Legislative decree 30/06/2003, n.196
"Code regarding the protection of personal data"